Device that counts calories in your plate of foods invented

The device, which has been developed by scientists at General Electrical Global Study in Niskayuna, New York, calculates the body fat content, water material and fat of food and makes use of an equation to make an estimate of the calories contained.

“To my surprise she answered, ‘Does it immediately track the calories I consume?’ I advised her that that was crazy and not feasible,” Mr Webster wrote on Common Electric International Research’s web site. “For her birthday she nonetheless received an exercise check from me (and loves it), but I acquired something as well…an notion was born as I began to challenge no matter whether this actually was crazy and not possible.”

^{View scientist Matt Webster make clear his calorie-counting gadget}

Numerous men and women presently preserve an eye on their calories using tools like apps, but the estimates are not constantly appropriate – the regular cupcake, for example, might be 300 calories, but size and sort of frosting could suggest the a single you eat contains significantly fewer or far more calories.

The gadget is at present in the prototype stage and is cumbersome to use, but the group are operating on a more accessible dome-shaped model that would match simply above a plate of meals and could be marketed at excess weight-conscious consumers.

“We are hopeful that even more improvement of this technologies will outcome in a pushbutton device that will offer calorie content of your meal in an immediate,” stated Mr Webster.

Device that counts calories in your plate of foods invented

The Uncertain Long term Of A Once Very Promising Device For Decreasing Blood Stress

Following the magnificent crash and burn of the Symplicity HTN-3 trial at the American University of Cardiology two weeks in the past, the potential of renal denervation (RDN)– the after highly promising catheter technological innovation that a lot of imagined would remedy resistant hypertension– appears in doubt.

Although the gadget has not been approved in the US– and will not be accepted with out more clinical trials– in Europe and other areas it remains on the market place. So the inquiries about the technology’s future revolve close to the future route of study in the field and how the current renal denervation market place will be impacted by the trial outcomes.

The uncertainty and confusion is driven by the quite wide disparity between the findings of the Symplicity HTN-3 randomized managed trial, which found a vanishingly small blood stress decreasing effect for RDN when compared to controls who underwent a sham method, and the Symplicity global registry, which discovered a extremely huge remedy effect similar to that observed in all the other prior uncontrolled or poorly managed trials.

Medtronic, which manufactures the Symplicity RDN system and sponsored the Symplicity HTN-3 trial, explained that it “remains committed to advancing renal denervation.” The trial “confirmed the profound security of the Symplicity program,” the firm said. “We do not believe… that this trial proves renal denervation does not function further clinical research is essential to confirm this hypothesis.” The company said that “a panel of independent experts produced up of worldwide doctors and researchers… affirmed that Medtronic ought to continue to provide access to the Symplicity method as long as the business continues to study it, which we intend to do. Medtronic believes physicians need to make clinical selections based on the totality of proof, such as their personal independent expertise.”

Boston Scientific explained its own RDN technological innovation is “highly differentiated” from Medtronic’s and is “supported by compelling clinical evidence and a powerful clinical program.” The firm has nevertheless to figure out its subsequent methods.

Michael Böhm, who presented the registry findings at the American College of Cardiology meeting last month, supports the continued clinical use of the gadget, particularly in meticulously selected sufferers with uncontrolled hypertension who have exhausted other alternatives and when carried out by skilled operators. The operators in the registry, he stated, had far much more experience with the method than the operators in Symplicity HTN-3. Along with other individuals, he mentioned that there are at present no goal approaches to measure the technical good results of the method. It is possible, he explained, that the greater knowledge of the registry operators created much better results. Another argument employed to assistance the continued use of RDN is that it may be much more powerful in some population subgroups.

Many commenters at the ACC struggled to strike a delicate balance. There was wide agreement that analysis in renal denervation must proceed, but a lot of believed use of RDN outdoors of a clinical trial was difficult to justify. But because the device remains on the market place in many countries, and since there is minor precedent for removing a solution from the market place when it has gained approval in the absence of a security problem, some think that the choice to make use of RDN need to be left to the individual doctor.

Not Steve Nissen. ”I think revenue should be suspended,” Nissen informed Reuters. “You (now) have a trial with no proof it performs.” PK Shah advised Reuters that physicians in Europe “would be much better off carrying out the right clinical trials and possibly putting a brief-phrase moratorium” on RDN except in the context of a clinical trial.

The new president of the ACC, Patrick O’Gara, stated he thought that some sufferers may possibly have benefited from RDN. “We need to have to convene a group of authorities to weigh the positives and negatives of a moratorium,” O’Gara told Reuters.

Speaking on behalf of the European Society of Cardiology, François Schiele advised me that RDN “should not be used except in clinical trials,” but he was clearly unhappy with the current predicament. As a former strong believer in RDN, he stated “it is difficult for me to recognize that it does not function.”

At a Late Breaker Deep Dive session Robert Califf explained that physicians should ”hold off on clinical use until finally a person can produce rigorous supportive data utilizing God’s gift of randomization.” He also said it “would be great to have a practical assay” to measure the impact of the catheter process.

Milton Packer defended the use of sham procedures in clinical trials because “there’s so much bias in the wonderment of getting done something to someone.” “Procedures,” he said, “are fundamentally a religious expertise.”

Darrel Francis, who predicted early on that Symplicity HTN-3 would not meet its major endpoint, mentioned that the registry does send “a resoundingly clear message” that Symplicity “is safe, which is of paramount importance for sufferers.” But the benefits of Symplicity HTN-three “teach essential lessons in human behaviour, underlining for us why we have to do blinded randomized controlled trials on these concerns if we want the true solution.”

We want to seem very carefully by means of the Symplicity 3 data to aid design and style future trials that will have a better likelihood of detecting effects that are smaller sized than we hoped, and could be a lot more variable than we guessed. I hope we are witnessing the origin of a new curiosity in meticulous methodology.

Comment: Renal denervation is an excellent illustration of the fact that there is no force in the known universe higher than the capacity of the human thoughts to deceive itself. People who now deny the significance of Symplicity HTN-3 and advocate the continued clinical utilization  of RDN join the chorus of deniers who for so prolonged supported  other ineffective procedures like the Vineberg method and transmyocardial laser revascularization.

It is even now completely attainable that RDN will 1 day be located to be beneficial. But right up until then– right up until there is some way to in fact measure the effectiveness of personal procedures and until the clinical advantages of RDN are rigorously demonstrated in stringent clinical trials– the technological innovation should not be given to any person outdoors the setting of a clinical trial.

It is been drummed into all of us that randomized trials make proof and observational research create hypotheses. My sense is that those who advocate the continued clinical use of RDN outdoors of clinical trials have switched these ideas around. They use the registry information as proof to help continued use of RDN and use the  randomized managed trial to create the hypothesis that RDN must not be employed. They ought to buy their priorities.

The Uncertain Long term Of A Once Very Promising Device For Decreasing Blood Stress

On the web device could be employed to recognize public figures" health care care, say critics

OmegaSolver had entry to NHS hospital episode statistics and supplied an ‘internal database [which] tracks real sufferers inside each hospital within England’. Photograph: Luca DiCecco/Alamy

An on-line device that claimed to be able to use NHS patient hospital data to reveal treatment “appropriate from preliminary diagnosis until the current day” has been pulled from the web right after privacy campaigners warned it could be employed to determine the exact particulars of healthcare care for people in the public eye.

OmegaSolver, a organization founded final yr, had access to NHS hospital episode statistics and supplied an “internal database [which] tracks actual sufferers inside of every hospital within England providing … up-to-date data for every illness spot”. The firm explained its clients integrated drugs companies.

However, the firm’s site was closed down last week following press inquiries to the well being authorities relating to the release of “patient-level” information to the company.

On Sunday it had emerged that a billion NHS patient data have been offered to a subsidiary of Chime Communications, a single of the country’s greatest PR and marketing and advertising companies, which had been functioning with the pharmaceutical sector.

These revelations will place stress on to the Overall health and Social Care Details Centre (HSCIC), the arm’s-length entire body set up to house all of England’s patient information, which says it will release within a fortnight the complete record of organizations, government agencies and charities that have been handed medical information.

Privacy campaigners explained that if the OmegaSolver on-line tool’s claims had been appropriate then the health care histories of individuals in public daily life could very easily be tracked. Phil Booth of MedConfidential pointed out the date when the Labour leader, Ed Miliband, had surgical procedure on his nose to deal with a sleep issue and the hospital exactly where the operation took spot had been in the “public domain”.

“It seems to be like anyone with entry [to the on-line device] could pinpoint and read through off the health-related histories of prominent political figures or pretty significantly anyone who’s had an accident or health care method reported in the press or on the internet. Nick Clegg’s wife’s broken elbow, Tony Blair’s catheter ablation, Ed Miliband’s nose operation – all reported in the media, providing adequate info to spot one occasion and then read across their each and every hospital visit. Ministers and officials declare your information will be anonymous, but it isn’t.”

In response the business explained that its Patient Analyser device, which seemed to track personal sufferers, was an “illustrative instance only”.

It added: “Privacy of the personal is one particular of the basic concepts which underpins the terms and problems governing access to this data, and OmegaSolver takes its commitment to preserving patient confidentiality quite seriously. Measures are in location to make confident that the identity of a patient is in no way found. OmegaSolver has access to data products and examination and makes these available for grouping and linkage functions only.”

The HSCIC said the company had taken down its web site. In a statement the centre stated: “We have been in get in touch with with OmegaSolver and, although discussions are ongoing, they have assured us that the screengrab offered demonstrates aggregated patient information and does not represent the expertise of an personal.”

Nonetheless, the details centre came beneath fire from MPs on the potent health pick committee in excess of its obvious reluctance to get action.

Barbara Keeley, a Labour member of the committee, stated: “We have noticed examples of organisations promoting applications which website link and then show comprehensive info about individual sufferers. It is clear that this data could be linked with other data about that man or woman which means the state of their overall health could then be tracked.”

“Examples have been offered of politicians and their family members who obtained publicity when they had an accident or an operation and were handled in the NHS. If media or social media reports on them can be linked with hospital patient data to track the state of that person’s health, it is of very real concern.”

“It is disturbing that patients are nonetheless being left in the dark about industrial utilizes of their confidential health information. I am asking concerns of wellness ministers about business re-use licences and regardless of whether these will now be revoked and the patient information deleted. I am also asking for audits to be accomplished so that individuals can be reassured that their confidential healthcare details is no longer becoming commercially exploited.”

On the web device could be employed to recognize public figures" health care care, say critics

No, An Apple Device Won"t Tell You If You happen to be Obtaining A Heart Assault

No a single knows for certain but Apple appears to be strongly interested in including healthcare applications and technologies to its existing and future items. We know that Apple has patented a heart sensor that could be integrated in a potential iPhone or iWatch, although it looks much more very likely that it would be utilised for safety rather than health functions. We also know that prime Apple executives have met with FDA commissioner Margaret Hamburg and best FDA gadget regulators, though the details of their discussion have not been disclosed.

But one new report on SF Gate is nearly surely incorrect: an Apple device will not be capable to inform you if you’re about to have a heart assault.

 Apple is exploring ways to measure noise “turbulence” as it applies to blood flow. The business would like to develop application and sensors that can predict heart attacks by identifying the sound blood tends to make as it tries to move via an artery clogged with plaque, the source said.

Even with Apple’s astonishing $ 150 billion money reservoir, this kind of advance would seem unlikely any time quickly. Cardiovascular researchers have been working for decades attempting to uncover far better techniques to accurately predict heart attacks. They’ve learned a lot in excess of the years but there is practically nothing that’s even shut to clinical actuality.

I asked a bunch of cardiologists for their ideas. None considered quite extremely of the prospect.

Sameer Bansilal, a cardiologist at Mt. Sinai in New York, said:

Although its enticing to envision that the view will magically predict heart attacks, the reality is that this kind of sensors rely on surrogates such as heart price, sympathetic tone and peripheral vascular resistance which can only offer element of the story, allow alone predict a specific artery becoming clogged.

Dave Albert, the inventor of the AliveCor mobile ECG,

Heart Attacks take place most usually when a coronary plaque ruptures, making a clot and obstructing blood movement to the heart. This obstruction in the coronary arteries has Absolutely nothing to do with turbulent blood movement in the radial or ulnar arteries in the wrist.

(The AliveCor is a excellent instance of mobile health engineering now accessible in the actual planet. Just last week the business announced that it had acquired FDA clearance to market the gadget more than-the-counter. Previously, purchase of the device had essential a physician’s prescription.)

Even Eric Topol, a properly-acknowledged cardiologist and technological innovation evangelist who is usually enthusiastic about new technologies, thinks this approach is unlikely to fulfill the hype. In a tweet he stated, “We’d all like to get this done, but this technique unlikely.”

But these adverse remarks shouldn’t propose that the converging trends of wearable computers and enhanced biosensors will not be essential. I suspect that new devices– in your pocket, on your wrist, in your eyeglasses– will sooner or later bring a new computing revolution, and there can be tiny question that wellness care will be transformed along with almost everything else. But for now I wouldn’t count on new technology to tell you when and if you are possessing a heart assault.

No, An Apple Device Won"t Tell You If You happen to be Obtaining A Heart Assault

Pivotal Medtronic Trial For "Breakthrough" Blood Stress Device Goes Down The Tubes

The hypertension local community woke up this morning to a huge dose of reality with an announcement by Medtronic that the a lot-anticipated SYMPLICITY HTN-three trial of its novel renal denervation device had failed to meet its main efficacy endpoint. Renal denervation has been broadly touted as a breakthrough merchandise that could drastically reduce blood strain by as much as 30 mm Hg, permitting physicians to remedy the most significant type of higher blood pressure, resistant hypertension.

“SYMPLICITY HTN-three met its major security endpoint connected to the incidence of key adverse occasions one month following randomization and renal artery stenosis to six months,” stated Deepak Bhatt, the co-principal investigator of the trial, in the Medtronic press release. “Importantly, nonetheless, the trial did not meet its primary efficacy endpoint.” To show efficacy in the trial blood pressure in the treatment method arm would have essential to be 10 mm Hg decrease than in the handle arm.

Medtronic mentioned that simply because no security considerations emerged in the trial, “no particular action is currently indicated for sufferers who have had the renal denervation procedure with the Symplicity method.” The organization mentioned it will assemble a panel of independent advisors “to make suggestions about the potential of the global hypertension clinical trial system.”  Until then Medtronic mentioned it would suspend enrollment in ongoing trials, including the SYMPLICITY HTN-4 trial studying renal denervation in individuals with much less serious varieties of hypertension. Symplicity will still be accessible in Europe and other markets where it has been accredited and the firm will carry on its international submit-market surveillance registry as nicely as studies that are evaluating other non-hypertension indications for the gadget.

Wells Fargo analyst Larry Biegelsen stated that the news means that that Medtronic is unlikely to achieve US approval for the gadget with no very first operating yet another trial.

Until finally just lately the forecast for renal denervation had been very optimistic. In December 2012 the American Heart Association listed renal denervation as one of its top advances of 2012 and there had been glowing reports in health-related journals and continuing healthcare education applications as nicely as the well-known press. A single newspaper quoted a former president of the American Heart Association: “It makes one particular dizzy to feel about the following set of advantages that stick to.”

Much more sensible expectations started to seem in 2013. As I reported last summertime, a paper published in Heart showed that the big reductions in blood stress seen in earlier clinical trials of renal denervation were most likely a solution of serious flaws in the style of these trials. Right up until SYMPLICITY HTN-3 the renal denervation trials had been largely uncontrolled, unblinded, and had utilized workplace-primarily based blood stress measurements rather than the far a lot more trustworthy and consistent ambulatory blood pressure monitoring. The senior writer of the Heart paper, Darrel Francis,  predicted that ”people are going to be severely disappointed” by the benefits of SYMPLICITY HTN-3.

In December St. Jude confirmed that it had halted enrollment in its EnligHTN IV trial, which was the pivotal trial for its very own renal denervation gadget.  Renal denervation items are at present offered in Europe and elsewhere from Medtronic, St. Jude Health-related, Boston Scientific, Covidien, Recor, and Terumo.

Pivotal Medtronic Trial For "Breakthrough" Blood Stress Device Goes Down The Tubes